Long-Term Longitudinal QoL in Patients Undergoing EEA
A Prospective Longitudinal Quality of Life Study in Patients Undergoing Endoscopic Endonasal Skull Base Surgery
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Megan Frost, BS
- Phone Number: 614-685-8622
- Email: Megan.Frost@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient is scheduled to undergo endoscopic endonasal surgery. Multiple, staged surgeries are not exclusionary
- 18 years of age or older
- The subject must in the investigator's opinion, be psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent
Exclusion Criteria:
- Patient is a prisoner
- Patient is not English speaking
- Patient is not expected to survive until the 2-year follow-up
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PROMIS-29 quality of life outcome measures for patients undergoing endoscopic endonasal surgeries.
Time Frame: 24-months post-operatively
|
This study aims to better understand the long-term overall quality of life of patients undergoing endoscopic endonasal surgery using modern sinonasal reconstruction techniques.
The PROMIS-29 metric, an overall quality of life metric, will be used to better understand quality of life for patients undergoing this procedure.
|
24-months post-operatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ASK Nasal-12 questionnaire used to measure normal time of healing for patients undergoing endoscopic endonasal surgery
Time Frame: 24 months post-operatively
|
This study aims to better understand the overall nose function in patients undergoing endoscopic endonasal surgery using modern sinonasal techniques.
The ASK Nasal-12 metric is designed to evaluate nose overall nose function such as post-nasal drip, ability to smell, and pain.
|
24 months post-operatively
|
|
Number of patients with long-term quality of life risk factors using PROMIS-29
Time Frame: 24 months post-operatively
|
This study aims to better understand the number of long-term risk factors for patients undergoing endoscopic endonasal surgeries using modern sinonasal reconstruction techniques.
This will be done using the PROMIS-29 metric along with patient data.
|
24 months post-operatively
|
|
Number of patients with long-term procedural comorbidities using ASK-Nasal 12.
Time Frame: 24 months post-operatively
|
This study aims to better understand the number of long-term comorbidities for patients undergoing endonasal endoscopic surgeries using modern sinonasal reconstruction techniques.
This will be done using the ASK-Nasal 12 metric along with patient data.
|
24 months post-operatively
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Kyle Wu, MD, Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Neoplasms
- Pathological Conditions, Anatomical
- Neoplasms by Histologic Type
- Endocrine Gland Neoplasms
- Neoplasms, Glandular and Epithelial
- Congenital Abnormalities
- Hernia
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Nervous System Neoplasms
- Sarcoma
- Neoplasms, Connective and Soft Tissue
- Neuroectodermal Tumors, Primitive, Peripheral
- Neuroectodermal Tumors, Primitive
- Neoplasms, Connective Tissue
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Central Nervous System Neoplasms
- Cranial Nerve Diseases
- Nervous System Malformations
- Hypothalamic Diseases
- Hypothalamic Neoplasms
- Supratentorial Neoplasms
- Brain Neoplasms
- Pituitary Diseases
- Neural Tube Defects
- Olfactory Nerve Diseases
- Neuroblastoma
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Pathological Conditions, Signs and Symptoms
- Meningioma
- Pituitary Neoplasms
- Craniopharyngioma
- Chondrosarcoma
- Chordoma
- Esthesioneuroblastoma, Olfactory
- Central Nervous System Cysts
- Encephalocele
Other Study ID Numbers
Other Study ID Numbers
- 2019H0225
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.